Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of docetaxel with and without prednisone in metastatic prostate cancer
2016-001269-10Phase 4Completed
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Jun 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of docetaxel in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Docetaxel AUC with and without prednisone. Started Jun 2016; status: completed.
02
Drugs
docetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-001269-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001269-10.